2.15
-0.03 (-1.38%)
| Previous Close | 2.18 |
| Open | 2.18 |
| Volume | 1,459,432 |
| Avg. Volume (3M) | 1,954,321 |
| Market Cap | 800,356,928 |
| Price / Sales | 2.80 |
| Price / Book | 1.35 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 |
| Profit Margin | -87.05% |
| Operating Margin (TTM) | -29.42% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | -14.20% |
| Total Debt/Equity (MRQ) | 118.03% |
| Current Ratio (MRQ) | 3.88 |
| Operating Cash Flow (TTM) | -127.00 M |
| Levered Free Cash Flow (TTM) | -54.07 M |
| Return on Assets (TTM) | -13.28% |
| Return on Equity (TTM) | -33.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Standard BioTools Inc. | Bearish | Bearish |
Stockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.25 |
|
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 72.14% |
| 52 Weeks Range | ||
| Median | 2.50 (16.28%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 31 Oct 2024 | 2.50 (16.28%) | Buy | 1.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2024 | Announcement | Standard BioTools Appoints Alex Kim as Chief Financial Officer |
| 31 Oct 2024 | Announcement | Standard BioTools to Participate in Upcoming Investor Conferences |
| 30 Oct 2024 | Announcement | Standard BioTools Reports Third Quarter 2024 Financial Results |
| 16 Oct 2024 | Announcement | Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 |
| 24 Sep 2024 | Announcement | Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform |
| 18 Sep 2024 | Announcement | Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) |
| 26 Aug 2024 | Announcement | Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |